Limits...
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG - Br. J. Cancer (2002)

Bottom Line: The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties.Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide.Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. kdredge@sghms.ac.uk

Show MeSH

Related in: MedlinePlus

Inhibition of angiogenesis as demonstrated by the reduction of tubule development following co-culture for 11 days with SelCIDs (A) or with thalidomide or IMiDs (B) in the human angiogenesis model. The effect of suramin or VEGF on tubule development is also shown. . *=P<0.05 vs control (Dunnett's test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376196&req=5

fig2: Inhibition of angiogenesis as demonstrated by the reduction of tubule development following co-culture for 11 days with SelCIDs (A) or with thalidomide or IMiDs (B) in the human angiogenesis model. The effect of suramin or VEGF on tubule development is also shown. . *=P<0.05 vs control (Dunnett's test).

Mentions: Illustrates the effect of a thalidomide analogue, IMiD-1 (C,F) and suramin (B,E) in comparison to their relative controls (A,D) on microvessel outgrowths in the rat aorta assay (top row) and on tubule development in the human angiogenesis model (bottom row).


Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG - Br. J. Cancer (2002)

Inhibition of angiogenesis as demonstrated by the reduction of tubule development following co-culture for 11 days with SelCIDs (A) or with thalidomide or IMiDs (B) in the human angiogenesis model. The effect of suramin or VEGF on tubule development is also shown. . *=P<0.05 vs control (Dunnett's test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376196&req=5

fig2: Inhibition of angiogenesis as demonstrated by the reduction of tubule development following co-culture for 11 days with SelCIDs (A) or with thalidomide or IMiDs (B) in the human angiogenesis model. The effect of suramin or VEGF on tubule development is also shown. . *=P<0.05 vs control (Dunnett's test).
Mentions: Illustrates the effect of a thalidomide analogue, IMiD-1 (C,F) and suramin (B,E) in comparison to their relative controls (A,D) on microvessel outgrowths in the rat aorta assay (top row) and on tubule development in the human angiogenesis model (bottom row).

Bottom Line: The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties.Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide.Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. kdredge@sghms.ac.uk

Show MeSH
Related in: MedlinePlus